1.中国中医科学院眼科医院,北京市石景山区鲁谷路33号,100040
2.中国中医科学院西苑医院脾胃病研究所
3.广州中医药大学第一附属医院
通信作者:txdly@sina.com
收稿:2025-06-24,
修回:2025-11-20,
纸质出版:2026-02-17
移动端阅览
温艳东,杨治,黄绍刚等.肠易激综合征的中医诊疗现状、策略与展望[J].中医杂志,2026,67(04):404-409.
WEN Yandong,YANG Zhi,HUANG Shaogang,et al.Current Status,Strategies and Prospects of Traditional Chinese Medicine Diagnosis and Treatment for Irritable Bowel Syndrome[J].Journal of Traditional Chinese Medicine,2026,67(04):404-409.
温艳东,杨治,黄绍刚等.肠易激综合征的中医诊疗现状、策略与展望[J].中医杂志,2026,67(04):404-409. DOI: 10.13288/j.11-2166/r.2026.04.011.
WEN Yandong,YANG Zhi,HUANG Shaogang,et al.Current Status,Strategies and Prospects of Traditional Chinese Medicine Diagnosis and Treatment for Irritable Bowel Syndrome[J].Journal of Traditional Chinese Medicine,2026,67(04):404-409. DOI: 10.13288/j.11-2166/r.2026.04.011.
肠易激综合征(IBS)是一种以腹痛、排便习惯改变为主要表现的功能性肠病。近年来中医在IBS的证候分布、中药复方发掘及临床疗效评价、外治疗法及精神心理调节等多方面取得进展,但仍面临诊断标准过度依赖症状而缺乏生物标志物、缺乏高质量中药复方治疗IBS的循证依据等问题。提出中医诊疗应遵循整体观与辨证论治相结合、联合中医外治法(如针灸、穴位贴敷)、注重精神心理异常的个体化诊疗策略。未来应结合多组学技术、人工智能等方法,深化IBS的发病机制及中药复方研究,推动中医药在IBS诊疗中的标准化与国际化。
Irritable bowel syndrome (IBS) is a functional bowel disorder characterized primarily by abdominal pain and altered defecation habits. In recent years, traditional Chinese medicine (TCM) has made progress in multiple aspects of IBS research and treatment, including syndrome distribution, development of TCM formulas, clinical efficacy evaluation, external therapies, and psychosocial regulation. However, it still faces challenges such as over-reliance on symptomatic manifestations rather than biomarkers for diagnostic criteria, and the lack of high-quality evidence-based data supporting the efficacy of TCM formulas in treating IBS. This paper proposed that TCM diagnosis and treatment of IBS should adhere to the strategy of integrating the holistic concept with syndrome differentiation and treatment, combining TCM external therapies such as acupuncture, moxibustion and acupoint application), and emphasizing individualized diagnosis and treatment for psychosomatic abnormalities. Future research should integrate multi-omics technologies, artificial intelligence and other methods to deepen the understanding of the pathogenesis of IBS and the mechanisms of TCM formulas, so as to promote the standardization and internationalization of TCM in the diagnosis and treatment of IBS.
MEARIN F , LACY BE , CHANG L , et al . Bowel disorders [J]. Gastroenterology , 2016 , 18 : S0016-5085(16)00222 - 5 . doi: 10.1053/j.gastro.2016.02.031 http://dx.doi.org/10.1053/j.gastro.2016.02.031 .
ALMARIO CV , SHARABI E , CHEY WD , et al . Prevalence and burden of illness of Rome Ⅳ irritable bowel syndrome in the United States: results from a nationwide cross-sectional study [J]. Gastroenterology , 2023 , 165 ( 6 ): 1475 - 1487 .
OKA P , PARR H , BARBERIO B , et al . Global prevalence of irritable bowel syndrome according to Rome Ⅲ or Ⅳ criteria: a systematic review and meta-analysis [J]. Lancet Gastroenterol Hepatol , 2020 , 5 ( 10 ): 908 - 917 .
HANNA-JAIRALA I , DROSSMAN DA . Central neuromodulators in irritable bowel syndrome: why, how, and when [J]. Am J Gastroenterol , 2024 , 119 ( 7 ): 1272 - 1284 .
BARBARO MR , CREMON C , MARASCO G , et al . Mole-cular mechanisms underlying loss of vascular and epithelial integrity in irritable bowel syndrome [J]. Gastroenterology , 2024 , 167 ( 6 ): 1152 - 1166 .
中华中医药学会脾胃病分会 . 肠易激综合征中医诊疗专家共识(2024) [J]. 中医杂志 , 2024 , 65 ( 18 ): 1948 - 1956 .
中华医学会消化病学分会胃肠功能性疾病协作组 , 中华医学会消化病学分会胃肠动力学组 . 2020年中国肠易激综合征专家共识意见 [J]. 中华消化杂志 , 2020 , 40 ( 12 ): 803 - 818 .
李登帅 , 杜斌 , 单兆伟 . 单兆伟教授运用脾胃升降理论治疗肠易激综合征经验 [J]. 四川中医 , 2017 , 35 ( 5 ): 22 - 24 .
王昱茜 , 吕咪 , 张坤漓 , 等 . 基于因子分析和聚类分析的肠易激综合征证候证素分布研究 [J]. 中国中医药信息杂志 , 2024 , 31 ( 12 ): 163 - 168 .
SONG J , YANG L , SU S , et al . The diagnosis performance of the TCM syndromes of irritable bowel syndrome by gastroenterologists based on modified simple criteria compared to TCM practitioners: a prospective, multicenter preliminary study [J]. Evid Based Complement Alternat Med , 2020 , 2020 : 9507674 . doi: 10.1155/2020/9507674 http://dx.doi.org/10.1155/2020/9507674 .
TANG XD , ZHANG SS , HOU XH , et al . Post-marketing re-evaluation of Tongxiening granules in treatment of diarrhea-predominant irritable bowel syndrome: a multi-center, randomized, double-blind, double-dummy and positive control trial [J]. Chin J Integr Med , 2019 , 25 ( 12 ): 887 - 894 .
苏国彬 , 刘文华 , 陈海滨 , 等 . 以痛泻要方为基本方治疗肠易激综合征随机对照试验的质量评价 [J]. 中医杂志 , 2008 , 49 ( 12 ): 1077 - 1080 .
常晓丽 , 牟梓君 , 王正文 , 等 . 针灸治疗肠易激综合征的现状与趋势:基于CiteSpace的知识图谱可视化分析 [J]. 世界科学技术-中医药现代化 , 2025 , 27 ( 2 ): 474 - 483 .
雷淼娜 , 朱叶珊 , 石志敏 . 中药膏穴位贴敷治疗腹泻型肠易激综合征疗效观察 [J]. 四川中医 , 2013 , 31 ( 1 ): 135 - 137 .
国家食品药品监督管理总局 . 总局关于发布中药新药用于肠易激综合征临床研究技术指导原则等5个临床研究技术指导原则的通告(2017年第217号) [EB/OL].( 2017-12-27 )[ 2025-11-20 ]. https//www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20171227183101142.html https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20171227183101142.html .
LACY BE , PIMENTEL M , BRENNER DM , et al . ACG clinical guideline: management of irritable bowel syndrome [J]. Am J Gastroenterol , 2021 , 116 ( 1 ): 17 - 44 .
YAO X , YANG YS , CUI LH , et al . The overlap of upper functional gastrointestinal disorders with irritable bowel syndrome in Chinese outpatients:a multicenter study [J]. J Gastroenterol Hepatol , 2016 , 31 ( 9 ): 1584 - 1593 .
HÄUSER W , MARSCHALL U , LAYER P , et al . The prevalence, comorbidity, management and costs of irritable bowel syndrome [J]. Dtsch Arztebl Int , 2019 , 116 ( 27/28 ): 463 - 470 .
VANDVIK PO , WILHELMSEN I , IHLEBAEK C , et al . Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implications [J]. Aliment Pharmacol Ther , 2004 , 20 ( 10 ): 1195 - 1203 .
IRVINE AJ , CHER WD , FORD AC . Screening for celiac disease in irritable bowel syndrome: an updated systema-tic review and meta-analysis [J]. Am J Gastroenterol , 2017 , 112 ( 1 ): 65 - 76 .
DROSSMAN DA , HASLER WL . Rome Ⅳ functional GI disorders: disorders of gut brain interaction [J]. Gastroenterology , 2016 , 150 ( 6 ): 12571261 .
GWEE KA , GONLACHANVIT S , GHOSHAL UC , et al . Second Asian consensus on irritable bowel syndrome [J]. J Neurogastroenterol Motil , 2019 , 25 ( 3 ): 343 - 362 .
GWEE KA , LU CL , GHOSHAL UC . Epidemiology of irritable bowel syndrome in Asia: something old, something new, something borrowed [J]. J Gastroenterol Hepatol , 2009 , 24 ( 10 ): 1601 - 1607 .
KOLOSKI NA , JONES M , KALANTAR J , et al . The brain gut pathway in functional gastrointestinal disorders is bidirectional: a 12 year prospective population based study [J]. Gut , 2012 , 61 ( 9 ): 1284 - 1290 .
许东 , 王承党 , 李晓青 , 等 . 腹泻型肠易激综合征合并心理异常对肠道症状的影响 [J]. 中华消化杂志 , 2018 , 38 ( 9 ): 603 - 608 .
BLACK CJ , FORD AC . Irritable bowel syndrome:a spot⁃light on future research needs [J]. Lancet Gastroenterol Hepatol , 2021 , 6 ( 6 ): 419 - 422 .
ZHENG L , LU W , XIAO Q , et al . Assessing the post-treatment therapeutic effect of pinaverium in irritable bowel syndrome: a randomized controlled trial [J]. Sci Rep , 2021 , 11 ( 1 ): 13894 .
马金鑫 . 术苓健脾胶囊治疗腹泻型肠易激综合征的临床疗效观察 [D]. 延安 : 延安大学 , 2019 .
陈熹 , 杨婷 , 章从恩 , 等 . 缓痛止泻软胶囊治疗腹泻型肠易激综合征的临床疗效及安全性观察 [J]. 中国医院用药评价与分析 , 2023 , 23 ( 11 ): 1294 - 1296,1300 .
WEI X , WEN Y , WEI Y , et al . External therapy of traditional Chinese medicine for treating irritable bowel syndrome with diarrhea: a systematic review and meta-analysis [J]. Front Med (Lausanne) , 2022 , 9 : 940328 . doi: 10.3389/fmed.2022.940328 http://dx.doi.org/10.3389/fmed.2022.940328 .
陈亮亮 , 丁义侠 , 李学军 , 等 . 参苓白术散联合穴位贴敷治疗腹泻型肠易激综合征疗效观察 [J]. 吉林中医药 , 2024 , 44 ( 7 ): 817 - 822 .
范青 , 贾峻 , 卢燚 . 乌灵胶囊联合针灸治疗肝郁脾虚证腹泻型肠易激综合征的临床疗效及安全性 [J]. 辽宁中医杂志 , 2024 , 51 ( 2 ): 139 - 143 .
EIJSBOUTS C , ZHENG T , KENNEDY NA , et al . Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders [J]. Nat Genet , 2021 , 53 ( 11 ): 1543 - 1552 .
于淑琪 . 基于肝脾同调理论治疗腹泻型肠易激综合征的疗效观察 [D]. 沈阳 : 辽宁中医药大学 , 2025 .
龚欣杨 . 疏肝健脾宁心方治疗腹泻型肠易激综合征(肝郁脾虚证)伴焦虑抑郁状态的临床疗效观察 [D]. 武汉 : 湖北中医药大学 , 2024 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号